MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization.
Company profile
Ticker
MXCT
Exchange
Website
CEO
Douglas Doerfler
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Icon • Syneos Health • Medpace • Incyte • Zymergen • OmniAb ...
Former names
MAXCYTE INC
SEC CIK
Corporate docs
Subsidiaries
CCTI, Inc. ...
IRS number
522210438
MXCT stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
12 Jun 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
7 May 24
ARS
2023 FY
Annual report to shareholders
1 May 24
DEF 14A
Definitive proxy
26 Apr 24
10-K
2023 FY
Annual report
12 Mar 24
8-K
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
12 Mar 24
8-K
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
5 Mar 24
8-K
Departure of Directors or Certain Officers
26 Jan 24
8-K
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
8 Jan 24
Transcripts
MXCT
Earnings call transcript
2024 Q1
7 May 24
MXCT
Earnings call transcript
2023 Q3
8 Nov 23
MXCT
Earnings call transcript
2023 Q2
9 Aug 23
MXCT
Earnings call transcript
2023 Q2
9 Aug 23
MXCT
Earnings call transcript
2023 Q1
10 May 23
MXCT
Earnings call transcript
2022 Q4
15 Mar 23
MXCT
Earnings call transcript
2022 Q3
12 Nov 22
MXCT
Earnings call transcript
2022 Q2
11 Aug 22
MXCT
Earnings call transcript
2022 Q1
10 May 22
MXCT
Earnings call transcript
2021 Q4
23 Mar 22
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 22.25 mm | 22.25 mm | 22.25 mm | 22.25 mm | 22.25 mm | 22.25 mm |
Cash burn (monthly) | 8.09 mm | 1.30 mm | 4.09 mm | 3.95 mm | 3.52 mm | 2.33 mm |
Cash used (since last report) | 21.00 mm | 3.37 mm | 10.63 mm | 10.26 mm | 9.15 mm | 6.05 mm |
Cash remaining | 1.25 mm | 18.88 mm | 11.62 mm | 11.99 mm | 13.10 mm | 16.20 mm |
Runway (months of cash) | 0.2 | 14.5 | 2.8 | 3.0 | 3.7 | 7.0 |
Institutional ownership, Q1 2024
14.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 31 |
Opened positions | 8 |
Closed positions | 58 |
Increased positions | 9 |
Reduced positions | 11 |
13F shares | Current |
---|---|
Total value | 21.71 bn |
Total shares | 15.60 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Integrated Core Strategies | 5.75 mm | $25.64 mm |
Sofinnova Crossover I | 4.61 mm | $0.00 |
River & Mercantile Asset Management | 1.89 mm | $7.97 bn |
Chevy Chase Trust | 1.30 mm | $5.43 bn |
Willis Investment Counsel | 525.00 k | $2.20 bn |
BK Bank Of New York Mellon | 340.18 k | $1.43 bn |
Allspring Global Investments | 285.15 k | $1.19 bn |
Swiss National Bank | 173.50 k | $726.97 mm |
Valmark Advisers | 116.08 k | $486.38 mm |
USB U.S. Bancorp. | 95.85 k | $401.62 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Jun 24 | William W Brooke | Common Stock | Grant | Acquire A | No | No | 0 | 21,367 | 0.00 | 71,669 |
11 Jun 24 | William W Brooke | Stock Option Common Stock | Grant | Acquire A | No | No | 4.68 | 40,701 | 190.48 k | 40,701 |
11 Jun 24 | Balthrop Patrick J | Common Stock | Grant | Acquire A | No | No | 0 | 21,367 | 0.00 | 21,367 |
11 Jun 24 | Balthrop Patrick J | Stock Option Common Stock | Grant | Acquire A | No | No | 4.68 | 40,701 | 190.48 k | 40,701 |
11 Jun 24 | John Joseph Johnston | Common Stock | Grant | Acquire A | No | No | 0 | 21,367 | 0.00 | 141,950 |
11 Jun 24 | John Joseph Johnston | Stock Option Common Stock | Grant | Acquire A | No | No | 4.68 | 40,701 | 190.48 k | 40,701 |
11 Jun 24 | Yasir B. Al-Wakeel | Common Stock | Grant | Acquire A | No | No | 0 | 21,367 | 0.00 | 21,367 |
11 Jun 24 | Yasir B. Al-Wakeel | Stock Option Common Stock | Grant | Acquire A | No | No | 4.68 | 40,701 | 190.48 k | 40,701 |
11 Jun 24 | Erck Stanley C | Common Stock | Grant | Acquire A | No | No | 0 | 21,367 | 0.00 | 269,118 |
11 Jun 24 | Erck Stanley C | Stock Option Common Stock | Grant | Acquire A | No | No | 4.68 | 40,701 | 190.48 k | 40,701 |
News
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
8 May 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
8 May 24
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
8 May 24
MaxCyte Affirms 2024 Revenue Guidance For Core Business Revenue To Be Flat To 5% Growth
7 May 24
MaxCyte Q1 2024 GAAP EPS $(0.09) Beats $(0.12) Estimate, Sales $11.342M Beat $7.462M Estimate
7 May 24
Press releases
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
29 May 24
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
22 May 24
Vicore Expands and Strengthens its Board of Directors
14 May 24
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
7 May 24
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
10 Apr 24